ALIBABA-CLOUD
Alibaba Cloud, the data intelligence backbone of Alibaba Group, said today it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.
The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.
The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud’s solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.
While DingTalk might be better-known for supporting more than 120 million students across China with their live-streamed online classes, the team has taken it up a notch to launch DingTalk’s International Medical Expert Communication Platform , hosted on Alibaba Cloud. It provides a means of free communication for medical workers all over the world to directly contact doctors from medical institutions such as the First Affiliated Hospital of Zhejiang University and others in China, who have been on the frontline of the COVID-19 battle.
Through video conferencing and real-time AI translation into 11 languages (Arabic, Bahasa, Chinese, English, French, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), Alibaba Cloud aims to build a virtual community, inviting Chinese doctors to share their experiences and answer questions from global peers.
From Alibaba DAMO Academy, a global research initiative by Alibaba, three proven solutions are being made available via free trial for medical professionals and research institutes worldwide. Alibaba Cloud will work with local partners to deploy relevant services and solutions in accordance with local laws and regulations.
Epidemic Prediction Solution models epidemic characteristics of COVID-19 in a particular region, providing estimates of size, peak time and duration of the epidemic, as well as the spreading trends under three conditions - optimistic, neutral, and pessimistic. Based on machine learning, the algorithm was already tested on 31 provincial data in China and averaged 98% accuracy. It can serve as a reference to policymakers and medical researchers on prevention and control measures, medical resource allocation and travel advisories.
CT Image Analytics Solution is a CT image analytics technology service that can significantly improve testing accuracy and detection efficiency for diagnosing COVID-19. With deep-learning algorithms trained by data in China, the trained model can predict the probability of different pneumonia types, including the variety associated with COVID-19. It also performs computations of the proportion of lesions and the affected volume ratio to the entire lungs, by using the lung segmentation method. The whole test takes about 3 to 4 seconds to run and 15 to 16 seconds of transmission time, making it nearly 60 times faster than human detection. More than 160 hospitals in China are currently using the solution.
Genome Sequencing for Coronavirus Diagnostic Solution , an AI algorithm from Alibaba DAMO Academy and running on Alibaba Cloud, is a virus genome sequencing solution for coronavirus analytics, including viral genetic data screening, evolutionary analysis, protein structure analysis, and diagnostic reporting. It can complete the diagnosis of new coronavirus within 14 hours, which is five times faster than other available sequencing solutions in China. It can screen more than 20 people simultaneously, making the averaged time for each sample just around half an hour, much shorter than the normal two hours with the PCR method. The solution helps disease control centers, hospitals and clinics, and laboratories to address challenges such as insufficient nucleic acid detection capacity, high false-negative rates of the PCR method, and possible virus mutations.
Supporting advanced innovations during emergencies like COVID-19 requires extremely scalable supercomputing power. For this, Alibaba Cloud offers Elastic High-Performance Computing (E-HPC) Solution for Life Sciences , a cloud-native high-performance computing cluster solution designed for researchers working on life sciences applications, especially for Computational-Driven-Drug-Design (CDDD) and AI-Driven-Drug-Design (AIDDD). The solution already supports 20 research groups in China. For example, the intelligent CT diagnostic system on COVID-19 pneumonia developed by Tsinghua University can complete diagnosing in 10 seconds, and the performance of gene assembly by Sun Yat-sen University is accelerated by 25% utilizing the solution. Alibaba Cloud has also partnered with Global Health Drug Discovery Institute (GHDDI) in Beijing to launch an AI-driven-drug-discovery platform based on E-HPC.
For those looking to learn more about key lessons and experience from doctors and other medical personnel at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), the Jack Ma Foundation and Alibaba Foundation have also shared a handbook from the medical personnel covering what they’ve learned every step of the way, from screening to diagnosis and treatment of patients who contracted COVID-19. Medical personnel can download the handbook at https://covid-19.alibabacloud.com/ .
For more information about the above solutions available for global medical communities and businesses, please visit: https://www.alibabacloud.com/campaign/supports-your-business-anytime
Notes to the editors
The information in this press release should not be interpreted as offering medical advice or diagnostics, which should be given exclusively by authorized medical professionals in relevant jurisdiction. All data referred to are those as of writing of this summary, and Alibaba Cloud explicitly disclaim any warranty for accuracy or performance.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the data intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 16:25:00 CET | Press release
With an increased prize fund of US $7.2 million, the Zayed Sustainability Prize supports enterprises, nonprofit organisations and schools delivering transformative solutions.Entries are now open, with applicants invited to submit innovative, scalable sustainability solutions.Now in its 18th year, the Prize has positively impacted over 400 million people by expanding access to clean energy, water, food, healthcare and improving climate resilience. The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more incl
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release
Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 14:31:00 CET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 14:00:00 CET | Press release
Lucend Seed round led by Remarkable Ventures Climate (RVC) to bring Transparent AI insights to data center operators in the U.S. increasing operational efficiency by 40% Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise env
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 14:00:00 CET | Press release
Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU) The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol®-based drugs allowing to develop breakthrough therapies Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Pha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom